01—Abstract
Summary
Summary of the 8-K filed September 15, 2025. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (GH) filed an 8-K on September 15, 2025 disclosing the appointment of Alex M.
Azar II, former U.S. Secretary of Health and Human Services (2018–2021), to its Board of Directors. The Board increased its size from 10 to 11 members and named Azar a Class III director effective September 12, 2025, with a term expiring at the 2027 Annual Meeting. He was also placed on the Nominating and Corporate Governance Committee.
The event is governance-focused and carries no disclosed financial impact. Azar's compensation follows the standard Amended Non-Employee Director Compensation Program: a stock option award and a restricted stock unit award, each valued at $362,500a. Both vest in installments, with one-quarter vesting on the first anniversary of appointment and the remainder vesting monthly over the following three years, subject to continued service.
He is also entering the Company's standard indemnification agreement. The filing reports no arrangements or related-party transactions requiring disclosure under Item 404(a).
For investors, the appointment signals an effort to strengthen the Board's policy, government relations, and healthcare access expertise, which management tied to reimbursement, regulatory, and patient-access priorities. The filing itself does not quantify any operational or financial benefit, so the significance will depend on how the Company leverages his experience over time.
02—Key points
Key Highlights
- Alex M. Azar II, former U.S. HHS Secretary (2018–2021), appointed as a Class III director effective September 12, 2025
- Board size increased from 10 to 11 directors; Azar's term expires at the 2027 Annual Meeting
- Azar joins the Nominating and Corporate Governance Committee
- Initial director compensation of $362,500 in stock options plus $362,500 in RSUs, vesting over four years
- Standard indemnification agreement entered into; no related-party transactions disclosed under Item 404(a)
- Press release issued September 15, 2025 (Exhibit 99.1) highlighting his policy and healthcare access experience
- No direct financial impact or guidance changes disclosed in the filing
03—Questions
Frequently Asked Questions
Who is Alex M. Azar II and why is he relevant to Guardant Health?
Azar served as the 24th U.S. Secretary of Health and Human Services from 2018 to 2021, overseeing CMS, the FDA, and the CDC. He previously led Lilly USA and served as HHS General Counsel and Deputy Secretary. His government and industry experience is relevant to a diagnostics company navigating reimbursement, regulatory pathways, and patient access.
Does this appointment change Guardant's financial outlook?
The 8-K does not include any financial guidance or quantified impact. The appointment is a governance action, and the filing discloses no changes to revenue, earnings, or operating expectations.
How is Azar compensated as a director?
He receives the standard non-employee director package: a stock option award and an RSU award, each valued at $362,500. One-quarter of each vests on the first anniversary of his appointment, with the remainder vesting monthly over the following three years, subject to continued service.
Are there any conflicts of interest or related-party concerns?
The filing states there are no arrangements or understandings under which Azar was selected as a director, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Why did the Board increase its size to 11 members?
The filing discloses the expansion of the Board to 11 directors to accommodate Azar's appointment but does not state a further strategic rationale beyond the press release's emphasis on his policy and operating experience.
04—Continue